View More Recent Stories

Nov 19, 2024 07:48AM Piper Sandler Reiterates Neutral Rating on Apellis Pharmaceuticals (APLS)
Nov 7, 2024 07:13AM Apellis Pharmaceuticals (APLS) PT Lowered to $55 at Baird
Nov 6, 2024 07:53AM Apellis Pharmaceuticals (APLS) PT Lowered to $30 at Scotiabank
Nov 6, 2024 07:47AM Apellis Pharmaceuticals (APLS) PT Lowered to $32 at Piper Sandler
Nov 6, 2024 07:43AM Apellis Pharmaceuticals (APLS) PT Lowered to $40 at Oppenheimer
Nov 6, 2024 06:48AM Apellis Pharmaceuticals (APLS) PT Lowered to $57 at H.C. Wainwright
Nov 5, 2024 02:53PM Apellis Pharmaceuticals (APLS) PT Lowered to $47 at BofA Securities
Nov 5, 2024 07:14AM Apellis Pharmaceuticals, Inc. (APLS) Misses Q3 EPS by 17c
Oct 28, 2024 05:42AM Citi Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)
Oct 16, 2024 07:01AM Apellis Pharmaceuticals (APLS) Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
Oct 4, 2024 06:40AM Mizuho Reiterates Neutral Rating on Apellis Pharmaceuticals (APLS)
Oct 3, 2024 08:27AM Mizuho Reiterates Neutral Rating on Apellis Pharmaceuticals (APLS)
Sep 23, 2024 06:48AM Apellis Pharmaceuticals (APLS) PT Lowered to $92 at Baird
Sep 23, 2024 06:42AM Apellis Pharmaceuticals (APLS) PT Lowered to $39 at Mizuho
Sep 20, 2024 10:55AM Stifel Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)
Sep 20, 2024 06:27AM Apellis Pharmaceuticals (APLS) PT Lowered to $39 at Mizuho
Sep 20, 2024 06:14AM Apellis Pharmaceuticals (APLS) Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy in the EU
Sep 16, 2024 06:47AM Mizuho Reiterates Neutral Rating on Apellis Pharmaceuticals (APLS)
Sep 9, 2024 06:12AM Apellis Pharmaceuticals (APLS) PT Lowered to $61 at BofA Securities
Aug 12, 2024 06:44AM Apellis Pharmaceuticals (APLS) PT Raised to $42 at Mizuho
Aug 9, 2024 06:38AM Apellis Pharmaceuticals (APLS) PT Raised to $96 at Baird
Aug 8, 2024 12:32PM Apellis Pharmaceuticals (APLS) PT Raised to $82 at Jefferies
Aug 8, 2024 08:05AM Apellis Pharmaceuticals (APLS) shares surge after study results
Aug 8, 2024 07:01AM Apellis Pharmaceuticals (APLS) and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
Aug 8, 2024 06:57AM Apellis Pharmaceuticals (APLS) Halted, News Pending
Aug 2, 2024 06:48AM Apellis Pharmaceuticals (APLS) PT Lowered to $83 at H.C. Wainwright
Jul 26, 2024 06:19AM Apellis Pharmaceuticals (APLS) PT Lowered to $86 at Baird
Jul 2, 2024 11:51AM Apellis Pharmaceuticals (APLS) PT Lowered to $65 at Oppenheimer
Jul 1, 2024 06:33AM Apellis Pharmaceuticals (APLS) PT Lowered to $49 at Mizuho
Jun 28, 2024 06:59AM Apellis Pharmaceuticals (APLS) to Seek Re-Examination Following Negative EU CHMP Opinion for Pegcetacoplan
View More Recent Stories